Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a body mass index (BMI) of 18.0 - 40.0 kg/m\^2~* Meets criteria for the diagnosis of schizophrenia~* Resides in a stable living situation when not hospitalized~* Is willing and able to provide government-issued identification~* Additional criteria may apply~Exclusion Criteria:~* Has had a psychiatric hospitalization for more than 30 days during the 90 days before screening~* Subject initiated first antipsychotic treatment within the past 12 months, or \<1 year has elapsed since the initial onset of active-phase of schizophrenia symptoms~* Subject poses a current suicide risk~* Subject has a history of treatment resistance~* Subject has a history of poor or inadequate response to treatment with olanzapine~* Subject requires or has had electroconvulsive therapy (ECT) treatment in the 2-month period prior to screening~* Subject has a diagnosis of moderate or severe alcohol or drug use disorder~* Subject has a positive urine drug screen for opioids, amphetamine/methamphetamine, phencyclidine, or cocaine at screening~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Administered as a coated bilayer tablet
- Olanzapine (Type: ACTIVE_COMPARATOR): Administered as a coated bilayer tablet
- Placebo (Type: PLACEBO_COMPARATOR): Administered as a coated bilayer tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).